Related Experiment Video

Updated: Aug 6, 2026

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

The spliceosome component SNRPC promotes glioma progression by sustaining mitochondrial function and TNFAIP2

Peng Ma1,2, Jiang Wu3, Zhen Ma2

  • 1Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Cell Death & Disease
|July 17, 2026
PubMed

Insights

Small nuclear ribonucleoprotein C (SNRPC) drives glioma malignancy by impairing mitochondrial function and increasing proliferation. Targeting SNRPC offers a novel therapeutic strategy for this aggressive brain tumor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Human glioma is an aggressive brain tumor with poor outcomes, requiring new therapeutic targets.
  • The spliceosome component SNRPC is linked to cancer but its role in glioma is unknown.

Purpose of the Study:

  • To investigate the expression, function, and mechanisms of SNRPC in human glioma.
  • To determine if SNRPC is a potential therapeutic target for glioma.

Main Methods:

  • Bioinformatic analysis of SNRPC expression in glioma tissues and correlation with clinical data.
  • Functional studies using SNRPC knockdown (shRNA) and knockout (CRISPR/Cas9) in glioma cells.
  • Investigation of SNRPC's role in mitochondrial metabolism, cell cycle, apoptosis, and oncogene expression (TNFAIP2).
  • In vivo studies using subcutaneous and orthotopic glioma xenograft models.

Main Results:

  • SNRPC is upregulated in glioma, correlating with higher grade, aggressive subtypes, and poor prognosis.
  • SNRPC silencing/knockout inhibits glioma cell proliferation, migration, invasion, and induces cell cycle arrest and apoptosis.
  • SNRPC loss causes mitochondrial dysfunction (impaired respiration, ATP depletion, ROS production).
  • SNRPC regulates TNFAIP2 expression, promoting malignant phenotypes.
  • SNRPC knockdown/knockout suppresses tumor growth in vivo.

Conclusions:

  • SNRPC is a key driver of glioma malignancy, sustaining mitochondrial hyperfunction and promoting proliferation.
  • SNRPC is a potential prognostic biomarker and therapeutic target for human glioma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...